JP2013518055A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518055A5 JP2013518055A5 JP2012550170A JP2012550170A JP2013518055A5 JP 2013518055 A5 JP2013518055 A5 JP 2013518055A5 JP 2012550170 A JP2012550170 A JP 2012550170A JP 2012550170 A JP2012550170 A JP 2012550170A JP 2013518055 A5 JP2013518055 A5 JP 2013518055A5
- Authority
- JP
- Japan
- Prior art keywords
- val92ala
- axl
- asp87gly
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100011565 AXL Human genes 0.000 claims 24
- 102200028872 MMP7 V92A Human genes 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102200134147 KDM5C D87G Human genes 0.000 claims 12
- 235000001014 amino acid Nutrition 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 12
- 102100004159 GAS6 Human genes 0.000 claims 11
- 101700018422 GAS6 Proteins 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 102200025465 ZG16 G32S Human genes 0.000 claims 8
- 102220044222 rs587781255 Human genes 0.000 claims 8
- 102200071656 HBA2 A72V Human genes 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 6
- 108090001123 antibodies Proteins 0.000 claims 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 5
- 238000006011 modification reaction Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- 206010027476 Metastasis Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- 102200069144 BAHD1 E26G Human genes 0.000 claims 2
- 102220417394 HLA-A Q86R Human genes 0.000 claims 2
- 102200107800 TP53 F113L Human genes 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000029578 entry into host Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102220245301 rs1555596673 Human genes 0.000 claims 2
- 102220005273 rs33915112 Human genes 0.000 claims 2
- 229940009098 Aspartate Drugs 0.000 claims 1
- 208000000409 Breast Neoplasms Diseases 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 102200061280 DCLRE1B H61Y Human genes 0.000 claims 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 1
- 102200045113 FKRP V79M Human genes 0.000 claims 1
- 102200103617 FUT3 T105M Human genes 0.000 claims 1
- 206010073072 Gallbladder neoplasm Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 229960002989 Glutamic Acid Drugs 0.000 claims 1
- 102200082936 HBB E27K Human genes 0.000 claims 1
- 102200118220 HBB V112A Human genes 0.000 claims 1
- 102220411598 HLA-A D88N Human genes 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 102200014141 LGALS3 T98P Human genes 0.000 claims 1
- 102200091997 LRRN2 A19T Human genes 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 102200028859 MMP7 V92D Human genes 0.000 claims 1
- 102200028870 MMP7 V92G Human genes 0.000 claims 1
- 102200133672 MMUT Q109R Human genes 0.000 claims 1
- 108020004999 Messenger RNA Proteins 0.000 claims 1
- 210000002307 Prostate Anatomy 0.000 claims 1
- 102200003607 SELPLG T44A Human genes 0.000 claims 1
- 102200045752 SIAE N33S Human genes 0.000 claims 1
- 102200032988 SRY I90M Human genes 0.000 claims 1
- 102220379071 SRY T98A Human genes 0.000 claims 1
- 102200107789 TP53 T118A Human genes 0.000 claims 1
- 206010064390 Tumour invasion Diseases 0.000 claims 1
- 102200113900 UTP3 T23M Human genes 0.000 claims 1
- 102200023059 UTS2 S74N Human genes 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 102000037240 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 229920002106 messenger RNA Polymers 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 102220294442 rs1402849815 Human genes 0.000 claims 1
- 102220005408 rs33984024 Human genes 0.000 claims 1
- 102220234469 rs398123322 Human genes 0.000 claims 1
- 102220135902 rs61731470 Human genes 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (17)
- AXL膜貫通ドメインを欠き、野生型AXL配列と比べて少なくとも1つのアミノ酸修飾を含み、前記変更がGAS6への前記AXLポリペプチドの結合の親和性を増加させるものである、可溶性AXL変異体ポリペプチド。
- 野生型AXLポリペプチド(配列番号:1)のアミノ酸領域19−437、130−437、19−132、21−121、26−132、26−121及び1−437から成る群より選択される少なくとも1つのアミノ酸領域を含み、かつ、1つ以上のアミノ酸修飾が前記アミノ酸領域において生ずるものである、請求項1に記載の可溶性AXL変異体ポリペプチド。
- 野生型AXL配列(配列番号:1)の位置19、23、26、27、32、33、38、44、61、65、72、74、78、79、86、87、88、90、92、97、98、105、109、112、113、116、118若しくは127又はそれらの組み合わせにおける少なくとも1つのアミノ酸修飾を含む、請求項1に記載の可溶性AXL変異体ポリペプチド。
- 野生型AXL配列(配列番号:1)と比べて次の位置:(a)グリシン32;(b)アスパラギン酸87;(c)バリン92;及び(d)グリシン127におけるアミノ酸変更を含むものであるか、又は、野生型AXL配列(配列番号:1)と比べて次の位置:(a)グルタミン酸26;(b)バリン79;(c)バリン92;及び(d)グリシン127におけるアミノ酸変更を含むものである、請求項1に記載の可溶性AXL変異体ポリペプチド。
- 以下の群:
1)Gly32Ser,Asp87Gly,Val92Ala,及びGly127Arg,2)Glu26Gly,Val79Met,Val92Ala,及びGly127Glu,3)Asn33Ser,Ser74Asn,Asp87Gly,及びVal92Ala,4)Ala72Val,Ile97Arg,及びHis116Arg,
5)Gln78Glu,
6)Ala72Val,
7)Gln86Arg,Ile90Val,及びVal92Ala,
8)Ala72Val,及びVal92Asp,
9)Asp65Asn,及びAsp87Gly,
10)Asp87Gly,及びVal92Ala,
11)Glu27Lys,His61Tyr,Ala72Val,Asp88Asn,Val92Ala,及びThr98Ala,
12)Val92Ala,Gln109Arg,
13)Thr44Ala,Ala72Val,Ile90Val,Thr105Met,及びGlu129Lys,
14)Val92Gly,
15)Val92Ala,Val112Ala,Phe113Leu,及びThr118Ala,
16)Val92Ala,及びThr98Pro,
17)Glu27Gly,及びAsp87Gly,
18)Thr38Ile,及びVal92Ala,
19)Asp87Gly,
20)Thr23Met,及びVal92Ala,
21)Ala72Val,及びPhe113Leu,
22)Gln86Arg,Val92Ala,
23)Ala19Thr,Glu26Gly,Glu27Gly,及びVal92Ala,
24)Ile90Met,及びVal92Ala,
25)Gly32Ser,及びAsp87Gly,
26)Gly32Ser,及びVal92Ala,
27)Gly32Ser,及びGly127Arg,
28)Asp87Gly,及びGly127Arg,
29)Val92Ala,及びGly127Arg,
30)Asp87Gly,Val92Ala,及びGly127Arg,
31)Gly32Ser,Val92Ala,及びGly127Arg,
32)Gly32Ser,Asp87Gly,及びGly127Arg,
33)Gly32Ser,Asp87Gly,及びVal92Ala,並びに
34)Gly32Ser,Ala72Val,Asp87Gly,Val92Ala,及びGly127Arg,
から選択される野生型AXL配列(配列番号:1)の一組のアミノ酸修飾を有する、請求項1に記載の可溶性AXL変異体ポリペプチド。 - 野生型AXL配列(配列番号:1)の位置32、72、87、92又は127又はそれらの組み合わせにおけるアミノ酸修飾を有し、GAS6に対する野生型AXLの結合親和性と同じかそれよりも高い結合親和性でGAS6に結合する、請求項1に記載の可溶性AXL変異体ポリペプチド。
- Fcドメインを含む融合タンパク質である、請求項1に記載の可溶性AXL変異体ポリペプチド。
- GAS6に対して少なくとも約1×10−8M又は1×10−9Mの親和性を有する、請求項1に記載の可溶性AXL変異体ポリペプチド。
- GAS6タンパク質に特異的に結合する、単離された抗体又はその断片。
- R299−T317、V364−P372、R389−N396、D398−A406、E413−H429及びW450−M468から成る群より選択されるGAS6の1つ以上のアミノ酸領域に含まれるエピトープに結合するものである、請求項9に記載の単離された抗体又はその断片。
- RMFSGTPVIRLRFKRLQPT(配列番号:3)、VGRVTSSGP(配列番号:4)、RNLVIKVN(配列番号:5)、DAVMKIAVA(配列番号:6)、ERGLYHLNLTVGGIPFH(配列番号:7)及びWLNGEDTTIQETVKVNTRM(配列番号:8)から成る群より選択されるアミノ酸領域に含まれるエピトープに結合するものである、請求項9に記載の単離された抗体又はその断片。
- 治療有効量の請求項1から8のいずれか一項に記載の1つ以上の可溶性AXL変異体ポリペプチド又は請求項9から11のいずれか一項に記載の抗体又はその断片、又は医薬的に許容され得るそれらの塩を含む、医薬組成物。
- 少なくとも1つの細胞傷害剤若しくは医薬的に許容され得る賦形剤又はそれらの組み合わせをさらに含む、請求項12に記載の医薬組成物。
- 哺乳動物患者における腫瘍の転移又は浸潤を処置、低減又は予防する方法に使用するための、請求項1から8のいずれか一項に記載の可溶性AXL変異体ポリペプチド、請求項9から11のいずれか一項に記載の抗体又はその断片、又は請求項12又は13に記載の組成物。
- 被験体において転移又は浸潤を起こす腫瘍の能力を判定する方法であって、
腫瘍を有する被験体からの生体試料におけるAXL又はGAS6活性のレベルを検出すること、及び
前記生体試料におけるAXL又はGAS6活性のレベルを所定レベルと比較すること
を含み;
前記所定レベルに比しての増加が腫瘍の浸潤又は転移素質を示す
ものである方法。 - 前記AXL又はGAS6活性レベルは、AXL又はGAS6のmRNA発現のレベル又はAXL又はGAS6タンパク質発現のレベルによって測定される、請求項15に記載の方法。
- 前記腫瘍は、卵巣腫瘍、***腫瘍、肺腫瘍、肝臓腫瘍、結腸腫瘍、胆嚢腫瘍、膵臓腫瘍、前立腺腫瘍及び膠芽腫から成る群より選択される腫瘍である、請求項14に記載のポリペプチド又は抗体、もしくは請求項15に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33647810P | 2010-01-22 | 2010-01-22 | |
US61/336,478 | 2010-01-22 | ||
PCT/US2011/022125 WO2011091305A2 (en) | 2010-01-22 | 2011-01-21 | Inhibition of axl signaling in anti-metastatic therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013518055A JP2013518055A (ja) | 2013-05-20 |
JP2013518055A5 true JP2013518055A5 (ja) | 2014-02-27 |
JP5965322B2 JP5965322B2 (ja) | 2016-08-03 |
Family
ID=44307615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012550170A Active JP5965322B2 (ja) | 2010-01-22 | 2011-01-21 | 抗転移療法におけるaxlシグナル伝達の阻害 |
Country Status (15)
Country | Link |
---|---|
US (2) | US8618254B2 (ja) |
EP (2) | EP2525824B1 (ja) |
JP (1) | JP5965322B2 (ja) |
KR (3) | KR20190019220A (ja) |
CN (2) | CN103154020B (ja) |
AU (2) | AU2011207381B2 (ja) |
BR (1) | BR112012018022A2 (ja) |
CA (2) | CA3056999A1 (ja) |
DK (2) | DK2525824T3 (ja) |
ES (2) | ES2928111T3 (ja) |
HK (1) | HK1245806A1 (ja) |
PT (2) | PT2525824T (ja) |
RU (1) | RU2556822C2 (ja) |
WO (1) | WO2011091305A2 (ja) |
ZA (2) | ZA201204866B (ja) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2556822C2 (ru) | 2010-01-22 | 2015-07-20 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Ингибирование axl сигнализации в антиметастатической терапии |
US9074192B2 (en) | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
US10844106B2 (en) | 2010-11-08 | 2020-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
US10197501B2 (en) | 2011-12-12 | 2019-02-05 | Kla-Tencor Corporation | Electron-bombarded charge-coupled device and inspection systems using EBCCD detectors |
US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
WO2013152031A1 (en) | 2012-04-04 | 2013-10-10 | Kla-Tencor Corporation | Protective fluorine-doped silicon oxide film for optical components |
US9496425B2 (en) | 2012-04-10 | 2016-11-15 | Kla-Tencor Corporation | Back-illuminated sensor with boron layer |
US9601299B2 (en) | 2012-08-03 | 2017-03-21 | Kla-Tencor Corporation | Photocathode including silicon substrate with boron layer |
WO2014035828A2 (en) * | 2012-08-27 | 2014-03-06 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl signaling in anti-metastatic therapy |
EA201690863A1 (ru) * | 2012-10-24 | 2016-09-30 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Нуклеиново-кислотная регуляция специфического белка блокировки роста 6 (gas6) |
US9151940B2 (en) | 2012-12-05 | 2015-10-06 | Kla-Tencor Corporation | Semiconductor inspection and metrology system using laser pulse multiplier |
US9426400B2 (en) | 2012-12-10 | 2016-08-23 | Kla-Tencor Corporation | Method and apparatus for high speed acquisition of moving images using pulsed illumination |
WO2014093707A1 (en) * | 2012-12-14 | 2014-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl signaling in primary tumor therapy |
PT3326622T (pt) | 2012-12-14 | 2021-04-07 | Univ Leland Stanford Junior | Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática |
US9478402B2 (en) | 2013-04-01 | 2016-10-25 | Kla-Tencor Corporation | Photomultiplier tube, image sensor, and an inspection system using a PMT or image sensor |
WO2015030849A1 (en) * | 2013-08-30 | 2015-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | High-affinity binding to gas6 |
US9347890B2 (en) | 2013-12-19 | 2016-05-24 | Kla-Tencor Corporation | Low-noise sensor and an inspection system using a low-noise sensor |
US9748294B2 (en) | 2014-01-10 | 2017-08-29 | Hamamatsu Photonics K.K. | Anti-reflection layer for back-illuminated sensor |
US9410901B2 (en) | 2014-03-17 | 2016-08-09 | Kla-Tencor Corporation | Image sensor, an inspection system and a method of inspecting an article |
EP2921857B1 (en) * | 2014-03-18 | 2017-05-03 | Medizinische Universität Wien | Soluble axl receptor tyrosine kinase in the diagnosis of cancer |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
US9525265B2 (en) | 2014-06-20 | 2016-12-20 | Kla-Tencor Corporation | Laser repetition rate multiplier and flat-top beam profile generators using mirrors and/or prisms |
US9767986B2 (en) | 2014-08-29 | 2017-09-19 | Kla-Tencor Corporation | Scanning electron microscope and methods of inspecting and reviewing samples |
CA2909669C (en) | 2014-10-20 | 2023-12-12 | Ruga Corporation | Antiviral activity of gas6 inhibitor |
EP3211080B1 (en) * | 2014-10-21 | 2020-09-16 | Kyowa Kirin Co., Ltd. | Anti human gas6 monoclonal antibodies |
CA2971406A1 (en) | 2014-12-18 | 2016-06-23 | Aravive Biologics, Inc. | Antifibrotic activity of gas6 inhibitor |
US9860466B2 (en) | 2015-05-14 | 2018-01-02 | Kla-Tencor Corporation | Sensor with electrically controllable aperture for inspection and metrology systems |
US10748730B2 (en) | 2015-05-21 | 2020-08-18 | Kla-Tencor Corporation | Photocathode including field emitter array on a silicon substrate with boron layer |
US10462391B2 (en) | 2015-08-14 | 2019-10-29 | Kla-Tencor Corporation | Dark-field inspection using a low-noise sensor |
US9865447B2 (en) | 2016-03-28 | 2018-01-09 | Kla-Tencor Corporation | High brightness laser-sustained plasma broadband source |
US10313622B2 (en) | 2016-04-06 | 2019-06-04 | Kla-Tencor Corporation | Dual-column-parallel CCD sensor and inspection systems using a sensor |
US10778925B2 (en) | 2016-04-06 | 2020-09-15 | Kla-Tencor Corporation | Multiple column per channel CCD sensor architecture for inspection and metrology |
US11662646B2 (en) | 2017-02-05 | 2023-05-30 | Kla Corporation | Inspection and metrology using broadband infrared radiation |
WO2018236194A1 (ko) * | 2017-06-23 | 2018-12-27 | 이화여자대학교 산학협력단 | Gas6 단백질 또는 이의 수용체 활성화제를 포함하는 섬유증의 예방 또는 치료용 조성물 |
US10806016B2 (en) | 2017-07-25 | 2020-10-13 | Kla Corporation | High power broadband illumination source |
US10690589B2 (en) * | 2017-07-28 | 2020-06-23 | Kla-Tencor Corporation | Laser sustained plasma light source with forced flow through natural convection |
US20200289613A1 (en) * | 2017-11-04 | 2020-09-17 | Aravive Biologics, Inc. | Methods of treating metastatic cancers using axl decoy receptors |
US11067389B2 (en) | 2018-03-13 | 2021-07-20 | Kla Corporation | Overlay metrology system and method |
US10714327B2 (en) | 2018-03-19 | 2020-07-14 | Kla-Tencor Corporation | System and method for pumping laser sustained plasma and enhancing selected wavelengths of output illumination |
US10568195B2 (en) | 2018-05-30 | 2020-02-18 | Kla-Tencor Corporation | System and method for pumping laser sustained plasma with a frequency converted illumination source |
US11114489B2 (en) | 2018-06-18 | 2021-09-07 | Kla-Tencor Corporation | Back-illuminated sensor and a method of manufacturing a sensor |
US10823943B2 (en) | 2018-07-31 | 2020-11-03 | Kla Corporation | Plasma source with lamp house correction |
US10943760B2 (en) | 2018-10-12 | 2021-03-09 | Kla Corporation | Electron gun and electron microscope |
US11262591B2 (en) | 2018-11-09 | 2022-03-01 | Kla Corporation | System and method for pumping laser sustained plasma with an illumination source having modified pupil power distribution |
US11114491B2 (en) | 2018-12-12 | 2021-09-07 | Kla Corporation | Back-illuminated sensor and a method of manufacturing a sensor |
US10811158B1 (en) | 2019-07-19 | 2020-10-20 | Kla Corporation | Multi-mirror laser sustained plasma light source |
US11844172B2 (en) | 2019-10-16 | 2023-12-12 | Kla Corporation | System and method for vacuum ultraviolet lamp assisted ignition of oxygen-containing laser sustained plasma sources |
CN110982791A (zh) * | 2019-12-26 | 2020-04-10 | 百泰生物药业有限公司 | 一种分泌axl抗体的杂交瘤细胞的制备筛选方法 |
US11761969B2 (en) | 2020-01-21 | 2023-09-19 | Kla Corporation | System and method for analyzing a sample with a dynamic recipe based on iterative experimentation and feedback |
US11848350B2 (en) | 2020-04-08 | 2023-12-19 | Kla Corporation | Back-illuminated sensor and a method of manufacturing a sensor using a silicon on insulator wafer |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
US5468634A (en) * | 1991-06-24 | 1995-11-21 | The University Of North Carolina At Chapel Hill | Axl oncogene |
AU697142B2 (en) * | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
US5538861A (en) | 1994-07-29 | 1996-07-23 | Amgen Inc. | DNA encoding a stimulating factor for the axl receptor |
US20030073169A1 (en) * | 1997-09-18 | 2003-04-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1483400A4 (en) | 2002-02-12 | 2007-07-11 | Quark Biotech Inc | USE OF THE AXL RECEPTOR FOR THE DIAGNOSIS AND TREATMENT OF A KIDNEY DISEASE |
EP1382969A1 (en) * | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
WO2004108748A2 (en) * | 2002-09-24 | 2004-12-16 | Dow, Kenneth, Centocor, Inc. | Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses |
CA2522984A1 (en) * | 2003-04-18 | 2004-10-28 | Novartis Ag | Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis |
CN101966338A (zh) * | 2003-06-09 | 2011-02-09 | 塞缪尔·瓦克萨尔 | 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法 |
JP2005278631A (ja) * | 2004-03-04 | 2005-10-13 | National Institute Of Advanced Industrial & Technology | Axlリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法 |
JP2008522162A (ja) * | 2004-11-24 | 2008-06-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド | Merの診断用および治療用の作用薬 |
EP1897940A4 (en) * | 2005-05-02 | 2009-04-15 | Toray Industries | COMPOSITION AND METHOD FOR DIAGNOSING ESOPHAGEAL CANCER AND METASTASIS OF ESOPHAGEAL CANCER |
US8097630B2 (en) * | 2006-10-10 | 2012-01-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors |
DK2078010T3 (da) | 2006-12-29 | 2014-04-28 | Rigel Pharmaceuticals Inc | Polycyklisk heteroaryl-substituerede triazoler, der er anvendelige som axl-hæmmere |
US8168415B2 (en) * | 2007-02-07 | 2012-05-01 | The Regents Of The University Of Colorado | Axl fusion proteins as Axl tyrosine kinase inhibitors |
US7633055B2 (en) * | 2007-03-08 | 2009-12-15 | Lumination Llc | Sealed light emitting diode assemblies including annular gaskets and methods of making same |
EP2139869A2 (en) | 2007-04-13 | 2010-01-06 | SuperGen, Inc. | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders |
EP2170395A1 (en) * | 2007-07-02 | 2010-04-07 | Wyeth LLC | Modulators of axl for use in treating bone disorders |
WO2009062112A2 (en) | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as antimicrobials |
EP2918605A1 (en) * | 2007-11-12 | 2015-09-16 | U3 Pharma GmbH | Axl antibodies |
AR077595A1 (es) | 2009-07-27 | 2011-09-07 | Genentech Inc | Tratamientos de combinacion |
US9074192B2 (en) * | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
RU2556822C2 (ru) | 2010-01-22 | 2015-07-20 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Ингибирование axl сигнализации в антиметастатической терапии |
MX336001B (es) | 2010-06-18 | 2016-01-07 | Genentech Inc | Anticuerpos anti-axl y metodos de uso. |
US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
PT3326622T (pt) * | 2012-12-14 | 2021-04-07 | Univ Leland Stanford Junior | Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática |
WO2014093707A1 (en) * | 2012-12-14 | 2014-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of axl signaling in primary tumor therapy |
-
2011
- 2011-01-21 RU RU2012136113/10A patent/RU2556822C2/ru active
- 2011-01-21 PT PT117352641T patent/PT2525824T/pt unknown
- 2011-01-21 ES ES17159334T patent/ES2928111T3/es active Active
- 2011-01-21 DK DK11735264.1T patent/DK2525824T3/en active
- 2011-01-21 JP JP2012550170A patent/JP5965322B2/ja active Active
- 2011-01-21 ES ES11735264.1T patent/ES2632345T3/es active Active
- 2011-01-21 CA CA 3056999 patent/CA3056999A1/en not_active Abandoned
- 2011-01-21 KR KR1020197004772A patent/KR20190019220A/ko active Application Filing
- 2011-01-21 PT PT171593346T patent/PT3241840T/pt unknown
- 2011-01-21 BR BR112012018022A patent/BR112012018022A2/pt not_active Application Discontinuation
- 2011-01-21 KR KR1020207023736A patent/KR20200100866A/ko not_active Application Discontinuation
- 2011-01-21 CN CN201180014940.0A patent/CN103154020B/zh active Active
- 2011-01-21 AU AU2011207381A patent/AU2011207381B2/en active Active
- 2011-01-21 EP EP11735264.1A patent/EP2525824B1/en active Active
- 2011-01-21 DK DK17159334.6T patent/DK3241840T3/da active
- 2011-01-21 CN CN201610819620.7A patent/CN107082805A/zh active Pending
- 2011-01-21 KR KR1020127021717A patent/KR101951410B1/ko active IP Right Grant
- 2011-01-21 WO PCT/US2011/022125 patent/WO2011091305A2/en active Application Filing
- 2011-01-21 EP EP17159334.6A patent/EP3241840B1/en active Active
- 2011-01-21 CA CA2786149A patent/CA2786149C/en active Active
-
2012
- 2012-06-29 ZA ZA2012/04866A patent/ZA201204866B/en unknown
- 2012-07-20 US US13/554,954 patent/US8618254B2/en active Active
-
2013
- 2013-07-24 US US13/950,111 patent/US9266947B2/en active Active
- 2013-10-15 ZA ZA2013/07676A patent/ZA201307676B/en unknown
-
2016
- 2016-08-08 AU AU2016213693A patent/AU2016213693A1/en not_active Abandoned
-
2018
- 2018-04-19 HK HK18105105.1A patent/HK1245806A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013518055A5 (ja) | ||
US11306124B2 (en) | Agonist agents of CD47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death | |
RU2012136113A (ru) | Ингибирование axl сигнализации в антиметастатической терапии | |
TWI826358B (zh) | 用於治療肌肉萎縮和骨疾病的新型雜合actriib配體陷阱蛋白及其用途與生產方法 | |
JP5947801B2 (ja) | アミロイド斑形成の阻害に有用なペプチド化合物 | |
US20210380678A1 (en) | Tissue-specific wnt signal enhancing molecules and uses | |
JP2012019790A5 (ja) | ||
JP2015212304A5 (ja) | ||
JP2013541335A5 (ja) | ||
JP2017113019A5 (ja) | ||
JP2014518883A5 (ja) | ||
JP2015533788A5 (ja) | ||
JP2014510518A5 (ja) | ||
JP2011188853A5 (ja) | ||
JP2020521478A5 (ja) | ||
CA2931309A1 (en) | Compositions and methods for treating pulmonary hypertension | |
JP2016531583A5 (ja) | ||
CA2702655A1 (en) | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof | |
KR20160045891A (ko) | 섬유성 질환의 치료 방법 | |
JP2014503180A5 (ja) | ||
JP2014523871A5 (ja) | ||
JP6345690B2 (ja) | 改変axlペプチド及び抗転移療法のaxlシグナル伝達阻害におけるその使用 | |
JP2015506961A5 (ja) | ||
Shemesh et al. | NKp44-derived peptide binds proliferating cell nuclear antigen and mediates tumor cell death | |
AU2015364437A1 (en) | Antifibrotic activity of GAS6 inhibitor |